Patents by Inventor Maik GROHMANN

Maik GROHMANN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Xanthine derivatives, their use as a medicament, and pharmaceutical preparations comprising the same
    Patent number: 11028104
    Abstract: The invention relates to a xanthine derivative defined by chemical formula I or a salt thereof, its use as a medicament, especially for use in the treatment of serotonin-related diseases or disorders, and a pharmaceutical preparation comprising the xanthine derivative. The novel xanthine compounds are capable of inhibiting tryptophan hydroxylases (TPH) involved in the biosynthesis of serotonin and are effective in influencing the serotonin level in the body.
    Type: Grant
    Filed: May 6, 2020
    Date of Patent: June 8, 2021
    Assignees: MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN, FORSCHUNGSVERBUND BERLIN E.V.
    Inventors: Michael Bader, Edgar Specker, Susann Matthes, Anja Schütz, Keven Mallow, Maik Grohmann, Marc Nazaré
  • XANTHINE DERIVATIVES, THEIR USE AS A MEDICAMENT, AND PHARMACEUTICAL PREPARATIONS COMPRISING THE SAME
    Publication number: 20200262847
    Abstract: The invention relates to a xanthine derivative defined by chemical formula I or a salt thereof, its use as a medicament, especially for use in the treatment of serotonin-related diseases or disorders, and a pharmaceutical preparation comprising the xanthine derivative. The novel xanthine compounds are capable of inhibiting tryptophan hydroxylases (TPH) involved in the biosynthesis of serotonin and are effective in influencing the serotonin level in the body.
    Type: Application
    Filed: May 6, 2020
    Publication date: August 20, 2020
    Applicants: MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN, FORSCHUNGSVERBUND BERLIN E.V.
    Inventors: Michael BADER, Edgar SPECKER, Susann MATTHES, Anja SCHÜTZ, Keven MALLOW, Maik GROHMANN, Marc NAZARÉ
  • Xanthine derivatives, their use as a medicament, and pharmaceutical preparations comprising the same
    Patent number: 10683309
    Abstract: The invention relates to a xanthine derivative defined by chemical formula I or a salt thereof, its use as a medicament, especially for use in the treatment of serotonin-related diseases or disorders, and a pharmaceutical preparation comprising the xanthine derivative. The novel xanthine compounds are capable of inhibiting tryptophan hydroxylases (TPH) involved in the biosynthesis of serotonin and are effective in influencing the serotonin level in the body.
    Type: Grant
    Filed: July 27, 2017
    Date of Patent: June 16, 2020
    Assignees: MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN, FORSCHUNGSVERBUND BERLIN E.V.
    Inventors: Michael Bader, Edgar Specker, Susann Matthes, Anja Schütz, Keven Mallow, Maik Grohmann, Marc Nazaré
  • XANTHINE DERIVATIVES, THEIR USE AS A MEDICAMENT, AND PHARMACEUTICAL PREPARATIONS COMPRISING THE SAME
    Publication number: 20190161503
    Abstract: The invention relates to a xanthine derivative defined by chemical formula I or a salt thereof, its use as a medicament, especially for use in the treatment of serotonin-related diseases or disorders, and a pharmaceutical preparation comprising the xanthine derivative. The novel xanthine compounds are capable of inhibiting tryptophan hydroxylases (TPH) involved in the biosynthesis of serotonin and are effective in influencing the serotonin level in the body.
    Type: Application
    Filed: July 27, 2017
    Publication date: May 30, 2019
    Applicants: MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN, FORSCHUNGSVERBUND BERLIN E.V.
    Inventors: Michael BADER, Edgar SPECKER, Susann MATTHES, Anja SCHÜTZ, Keven MALLOW, Maik GROHMANN, Marc NAZARÉ
  • Xanthine derivatives, their use as a medicament, and pharmaceutical preparations comprising the same
    Patent number: 10214530
    Abstract: The invention relates to a xanthine derivative defined by chemical formula I or a salt thereof, its use as a medicament, especially for use in the treatment of serotonin-related diseases or disorders, and a pharmaceutical preparation comprising the xanthine derivative. The novel xanthine compounds are capable of inhibiting tryptophan hydroxylases (TPH) involved in the biosynthesis of serotonin and are effective in influencing the serotonin level in the body.
    Type: Grant
    Filed: February 24, 2016
    Date of Patent: February 26, 2019
    Assignee: MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN
    Inventors: Michael Bader, Edgar Specker, Susann Matthes, Anja Schütz, Keven Mallow, Maik Grohmann, Marc Nazaré
  • XANTHINE DERIVATIVES, THEIR USE AS A MEDICAMENT, AND PHARMACEUTICAL PREPARATIONS COMPRISING THE SAME
    Publication number: 20180051025
    Abstract: The invention relates to a xanthine derivative defined by chemical formula I or a salt thereof, its use as a medicament, especially for use in the treatment of serotonin-related diseases or disorders, and a pharmaceutical preparation comprising the xanthine derivative. The novel xanthine compounds are capable of inhibiting tryptophan hydroxylases (TPH) involved in the biosynthesis of serotonin and are effective in influencing the serotonin level in the body.
    Type: Application
    Filed: February 24, 2016
    Publication date: February 22, 2018
    Applicants: Max-Delbrück-Centrum für Molekulare Medizin, Forschungsverbund Berlin e.V.
    Inventors: Michael BADER, Edgar SPECKER, Susann MATTHES, Anja SCHÜTZ, Keven MALLOW, Maik GROHMANN, Marc NAZARÉ